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Abstract 
Review on EZH2, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Identity 
Other names: ENX-1, ENX1, EZH1, EZH2b, 
KMT6, KMT6A, WVS, WVS2 
HGNC (Hugo): EZH2 
Location: 7q36.1 
Local order 
Based on MapViewer, gene flanking EZH2 
oriented on 7q35-q36 are: 
- CUL1 (cullin 1); 7q36.1 
- RNU7-20P (RNA, U7 small nuclear 20 
pseudogene); 7q36.1 
- EZH2; 7q35-q36. 
DNA/RNA 
Description 
The EZH2 gene is located on chromosome 7,  
starting from 148504464 and ends at 148581441 
bp. This gene encodes a member of the Polycomb-
group (PcG) family. PcG family members form 
multimeric protein complexes, which are involved 
in maintaining the transcriptional repressive state of 
genes. 
Transcription 
Multiple alternatively spliced transcript variants 
have been identified for this gene. These include 5 
histone-lysine N-methyltransferase EZH2 isoforms 
(-a/-b/-c/-d/-e). The first variant (a) has the longest 
isoform of histone-lysine N-methyltransferase 
EZH2. 
The second variant (b) does not have an in-frame 
exon and an in-frame segment in the coding region, 
while (c) and (d) variants lack an in-frame segment 
in the coding region and two in-frame segments in 
the coding region, respectively, as compared to (a) 
variant. The last variant (e) has an alternate 5' UTR 
exon and lacks an in-frame exon and two in-frame 
segments in the coding region, as compared to (a) 
variant. 
 
Figure 1. Location of EZH2 in chromosome 7, q35-36, which is located within 148504464 and 148581441 bp. 
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Figure 2. The interaction and effect of EZH2 in regulation of transcriptional repression. Polycomb complex 2 (PRC2) exerts 
methyltransferase activity to H3K27 via the SET domain of the EZH2 subunit. 
 
Protein 
Description 
EZH2 protein is the catalytic subunit of Polycomb 
Repressive Complex 2, one of the two-multimeric 
repressive complexes in the organization of the 
PcG. 
Function 
PcG proteins act as an important epigenetic 
mediator that can repress gene expression by 
forming multiple complexes leading to 
trimethylation at lysine 27 of histone H3 
(H3K27me3; Cao et al., 2002; Viré et al., 2006). On 
the one hand, EZH2 is a histone methyltransferase, 
which plays an important role in tumor 
development (Santos-Rosa and Caldas, 2005). 
Moreover, this protein might also play essential 
roles in the control of central nervous systems by 
regulating the dopamine receptor D4 (Unland et al., 
2014). 
Homology 
The EZH2 gene is conserved in chimpanzee, 
Rhesus monkey, dog, cow, mouse, rat, chicken, 
zebrafish, fruit fly, and mosquito. 
Mutations 
Note 
Several mutations have been reported in EZH2 
gene, which has been shown to be associated with 
different human diseases (e.g., Weaver syndrome, 
lymphoma and myeloid neoplasms). In particular, 
Morin and collaborators, found that the mutation of 
EZH2 Y641, within the SET domain, is correlated 
with poor prognosis in myeloid neoplasms. They 
observed various heterozygous mutations at Y641 
in 7% of follicular lymphomas and 22% of diffuse 
large cell B-cell lymphomas of germinal center 
origin (Morin et al., 2010), which increased the 
level of H3K27me3 (Chase and Cross, 2011). 
Furthermore EZH2 mutations have not yet been 
reported in several other human diseases such as 
pancreatic ductal adenocarcinoma, but we cannot 
exclude that such somatic alterations might occur.  
Moreover, more than 4941 single nucleotide 
variations (SNPs) have been reported in the EZH2 
gene (31th of January 2014, dbSNP), such as 
rs193921147, rs193921148, rs397515547, 
rs397515548, rs734004, rs12670401, rs6950683 
etc. 
Implicated in 
Human diseases 
Note 
EZH2 is a histone methyltransferase, which is 
involved in the regulation of cell fate, and 
maintaining the balance between self-renewal and 
differentiation (Chang et al., 2011; Cao et al., 2002; 
Lund et al., 2014). This protein acts as an 
epigenetic mediator that can suppress gene 
expression by histones methylation at H3k27 (Cao 
et al., 2002; Viré et al., 2006). EZH2 is up-
regulated in many tumors, such as breast and 
prostate cancer, which has been shown to be 
associated with tumor growth, invasion, and 
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metastasis as well as poor prognosis (Santos-Rosa 
and Caldas, 2005; Chang and Hung, 2012). 
Pancreatic cancer 
Note 
EZH2 is found to be overexpressed in a variety of 
carcinomas including pancreatic adenocarcinoma 
(PAC), and has been shown to be associated with 
decreased E-cadherin expression and poor 
prognosis in PAC patients (Toll et al., 2010). In 
particular, Toll and collaborators, evaluated the 
correlation of EZH2 with E-cadherin expression in 
54 pancreatic adenocarcinomas, 13 intraductal 
papillary mucinous neoplasms (IPMN), and 6 
chronic pancreatitis cases, and assessed response to 
gemcitabine in relation to EZH2 expression in 
tumor cells. This study showed that high EZH2 
expression in pancreatic adenocarcinoma was 
significantly associated with decreased E-cadherin 
expression and more aggressive disease. Moreover, 
they also observed high EZH2 expression in IPMN 
tissue with moderate to severe dysplasia, but not in 
chronic pancreatitis.  
In the study by Ougolkov and colleagues, EZH2 
was identified as an important factor in pancreatic 
ductal adenocarcinoma (PDAC) cell 
chemoresistance. In particular, they showed that 
EZH2 depletion by RNA-interference sensitized 
PDAC cells to gemcitabine (Ougolkov et al., 2008). 
Furthermore, in our recent study, we showed that 
inhibition of EZH2 by EZH2 inhibitor DZNeP 
synergistically increased the antiproliferative 
activity of gemcitabine (first line agent in treatment 
of PDAC) through inhibition of cell proliferation 
and migration, and increasing apoptosis (Avan et 
al., 2012). 
Chronic pancreatitis 
Note 
Mallen-St Clair and colleagues published an elegant 
study illustrating that the EZH2 connects 
pancreatitis to acinar cell regeneration, by providing 
a mechanism of protection against progression to 
cancerous lesions (Mallen-St Clair et al., 2012). In 
this study they showed that EZH2 is overexpressed 
in patients suffering from chronic pancreatitis. In 
particular, their findings revealed that EZH2 is 
constraining neoplastic progression through 
homeostatic mechanisms that control pancreatic 
regeneration (Mallen-St Clair et al., 2012). 
Prostate cancer 
Note 
Varambally and collaborators, in 2002, 
demonstrated that EZH2 is up-regulated in 
hormone-refractory, metastatic prostate cancer. 
They found that small interfering RNA against 
EZH2 reduced the EZH2 protein expression in 
prostate cells and inhibited cell proliferation in 
vitro, while ectopic expression of EZH2 in prostate 
cells induces transcriptional repression of a specific 
cohort of genes. They also showed that EZH2 up-
regulation was significantly associated with the 
progression of prostate cancer and poor clinical 
outcome (Varambally et al., 2002). Moreover, 
deletions of microRNA-101 in prostate cancer 
resulted as a negative regulator of EZH2 
expression, providing a possible mechanism for 
EZH2 overexpression (Cao et al., 2010). 
Breast cancer 
Note 
Kleer and collaborators explored the functional role 
of EZH2 in cancer cell invasion and breast cancer 
progression, and evaluated the expression of EZH2 
in 280 patients. They showed that EZH2 transcript 
and protein were consistently elevated in invasive 
breast carcinoma compared to normal breast 
epithelia. Moreover, tissue microarray analysis 
illustrated that the levels of EZH2 expression were 
strongly associated with breast cancer 
aggressiveness. In particular, EZH2 overexpression 
in immortalized human mammary epithelial cell 
lines stimulated anchorage-independent growth and 
cell invasion in the cells. In this study they 
identified EZH2 as a marker of aggressive breast 
cancer, which promotes neoplastic transformation 
of breast epithelial cells (Kleer et al., 2003). 
Bladder carcinoma 
Note 
Several studies have been shown the role of EZH2 
in bladder carcinomas (Weikert et al., 2005; Raman 
et al., 2005; Arisan et al., 2005). In particular, 
Weikert and collaborators, evaluated the EZH2 
expression in 37 bladder carcinomas using real-time 
reverse transcription-polymerase chain reaction 
(RT-PCR) and correlated the data with 
clinicopathological findings. They found that the 
mRNA levels of EZH2 were significantly higher in 
invasive bladder carcinomas (median value, 38.92) 
compared to non-invasive tumors (median value, 
15.51). Moreover, the level of EZH2 expression 
was significantly higher in grade-3, with respect to 
grade-1/2 lesions, suggesting its role in the 
progression of bladder tumors. In addition, 
increased EZH2 expression correlated with 
oncogenesis of the bladder (Arisan et al., 2005; 
Weikert et al., 2005). 
Gastric cancer 
Note 
Despite the complexity of stomach carcinogenesis, 
a number of markers identified as prognostic 
factors, including EZH2. Matsukawa and 
colleagues determined the expression of EZH2 in 
83 surgically removed human gastric cancer tissues 
and analyzed its association with the 
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clinicopathological features of human gastric 
cancers. Immunohistochemical analysis of the 
tissue samples and corresponding non-cancerous 
gastric mucosa demonstrated that EZH2 was more 
highly expressed in the cancerous than in the non-
cancerous tissues, and the expression levels of 
EZH2 were markedly associated with tumor size, 
depth of invasion, vessel invasion, lymph node 
metastasis and clinical stages. Furthermore, gastric 
cancer patients with high-level EZH2 expression 
had poorer prognosis, compared to those expressing 
low levels of EZH2 (Matsukawa et al., 2006). 
Lung cancer 
Note 
Several studies have investigated the biological role 
and prognostic value of EZH2 in lung cancer. 
Recently, Xia and colleagues demonstrated that 
inhibition of EZH2 by RNAi enhanced irradiation-
induced inhibition of human lung cancer growth in 
vitro and in vivo. They showed that irradiation in 
combination with the inhibition of EZH2 arrested 
A549 cells in the G1-S boundary, inhibited cell 
proliferation, increased the percentage of apoptotic 
cells in vitro, and reduced tumor size and increased 
survival in tumor xenograft (Xia et al., 2012). 
Another study evaluated the EZH2 expression in 
106 patients classified as stage I non-small cell lung 
cancer (NSCLC). They found that patients with 
positive EZH2 expression had a larger tumor size 
and survived significantly shorter, compared to the 
patients with low EZH2 expression. Moreover, in 
vitro studies showed that knockdown of EZH2 
expression in the NSCLC cell lines reduced the 
tumor growth rate and invasive activity, indicating 
that EZH2 promotes progression and invasion of 
NSCLC, and its expression can be considered as a 
novel prognostic biomarker in NSCLC (Huqun et 
al., 2012).  
Moreover, Lv and collaborators, in 2012 evaluated 
the expression of EZH2 in lung adenocarcinoma 
tissues and cell lines. They observed that EZH2 
overexpression in tumor tissue significantly 
correlated with histological differentiation, 
pathological tumor-node-metastasis stage and 
smoking history. Moreover, overexpression of 
EZH2 was also detected in cisplatin-resistant cancer 
cells with respect to cisplatin-sensitive cells, while 
inhibition of EZH2 inhibited cell proliferation and 
migration, and induced apoptosis in both cisplatin-
resistant and cisplatin-sensitive cell lines. These 
data suggested that EZH2 contributed to the 
progression of lung adenocarcinoma, and the 
suppression of EZH2 inhibited cell growth and 
sensitized cells to cisplatin in lung adenocarcinoma 
(Lv et al., 2012). Furthermore, Xu and 
collaborators, found a positive correlation between 
high EZH2 expression with pathologic stage, nodal 
involvement in lung cancer patients. In particular, 
they showed that overexpression of EZH2 was 
associated with reduced tissue inhibitor of 
metalloproteinase-3 expression, which was shown 
to be negatively associated with tumor metastasis in 
lung cancer (Xu et al., 2013). 
Hepatocellular carcinoma 
Note 
Sudo and collaborators investigated the expression 
of EZH2 in 66 patients with hepatocellular 
carcinoma (HCC), using RT-PCR, and correlated 
its expression with clinicopathological parameters. 
They observed that the expression levels of EZH2 
in tumor tissue specimens were significantly higher, 
compared to the non-tumor tissue specimens. 
Moreover, these analyses demonstrated that the 
incidence of cancer cell invasion into the portal 
vein was markedly increased in the group of 
patients with high EZH2 expression with respect to 
the patients with low EZH2 expression, while there 
was no difference in the disease-free survival rate 
between the two groups of patients (Sudo et al., 
2005). 
Hematological malignancies 
Note 
The role of EZH2 in hematological malignancies is 
still unclear. Several point mutations, resulting in 
gain-of-function, or inactivating mutations (loss-of-
function), have been observed in lymphoma and 
leukemia, suggesting its role as an oncogene or 
tumor-suppressor gene. Visser and collaborators, 
evaluated the expression of both multimeric PcG 
protein complexes (EZH2-EED- and a BMI1-
RING1- containing complex) in six cases of mantle 
cell lymphoma (MCL). They showed that MCL 
cells expressed BMI1-RING1, but not EZH2-EED, 
like normal mantle cells. Moreover, they showed 
that the up-regulation of EZH2 was associated with 
higher proliferation rate of haematopoietic cells 
(Visser et al., 2001).  
A recent study performed a comparative microarray 
analysis of gene expression in primary adult T-cell 
leukemia/lymphoma samples. This study found the 
higher levels of EZH2, RING1 and YY1 binding 
protein transcripts with enhanced levels of 
H3K27m3 in adult T-cell leukemia/lymphoma 
cells, compared with those in normal CD4 (+) T 
cells. They also showed that patients with high 
EZH2 expression had a significantly poorer 
prognosis, indicating a possible role of this gene in 
the oncogenesis and progression of this disease 
(Sasaki et al., 2011). Another gene expression 
profiling of Polycomb, Hox and Meis genes in 126 
patients with acute myeloid leukemia showed that 
the expression levels of EZH2 and MEL18 were 
significantly higher in patients with complex 
karyotype and lower in CBF-mutated patients. 
Moreover, comparisons between the PcG and PcG-
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regulated genes and clinical data demonstrated the 
correlations of genes involved in DNA methylation 
with apoptosis (BAX, Caspase 3) and multidrug-
resistance (MDR1, MRP), suggesting the role of 
PcG and PcG-regulated genes in leukaemogenesis 
(Grubach et al., 2008). Moreover, Xu and 
collaborators examined a heterogeneous 
myelodysplastic syndrome (MDS)/AML population 
known to harbor DNA methylation of tumor-
suppressor genes, such as p15INK4B. They 
observed that patients with p15INK4B gene 
methylation had a significantly higher expression of 
EZH2 with respect to the non-methylated 
counterparts, and the level of EZH2 expression 
correlated with poor clinical outcome (Xu et al., 
2011). 
Conversely, Nikoloski and collaborators 
demonstrated the role of EZH2 as tumor suppressor 
gene in myelodysplastic syndromes (MDS). In this 
study, they sequenced the EZH2 gene in 126 
patients with MDS. These analyses revealed that 
EZH2 gene was frequently mutated in MDS 
patients. Similarly, another recent study 
demonstrated that inhibition of EZH2 increased the 
tumorigenic potential and mortality of T cell acute 
lymphoblastic leukemia cells transplanted into 
NOD-SCID mice, suggesting the tumor suppressor 
role of PRC2 in human leukemia (Ntziachristos et 
al., 2012). 
Qi and collaborators recently developed an EZH2-
selective small-molecule inhibitor EI1 that binds to 
the S-adenosylmethionine of EZH2. They observed 
that inhibition of EZH2 by EI1 in diffused large B-
cell lymphomas cells carrying the Y641 mutations 
decreased the cell proliferation, cell cycle arrest, 
and enhanced apoptosis (Qi et al., 2012). Two other 
recent studies have demonstrated further advances 
in the therapeutic potential of EZH2 inhibition to 
treat lymphoma. Among the compounds, which 
have been developed so far, EPZ005687 and 
GSK126 have been found to induce apoptosis in 
lymphoma cell lines harboring Tyr641 mutations 
with minimal effect on WT cells, in vitro (Knutson 
et al., 2012) and in vivo (McCabe et al., 2012). In 
particular, McCabe and collaborators, showed that 
GSK126 molecule inhibited tumor growth and 
significantly increased survival of the mice carrying 
lymphoma cells (McCabe et al., 2012; Lund et al., 
2014).  
In aggregate, considering the dual function of 
EZH2, which has been shown to act as oncogene or 
tumor-suppressor gene in hematological 
malignancies, the therapeutic potential of EZH2 
inhibitors should be evaluated carefully, to ensure 
achievement of beneficial effect, rather than 
tumorigenic effect (Lund et al., 2014). 
Pediatric tumors of the central 
nervous system 
Note 
The dopamine receptor D4 (DRD4) is a G-protein-
coupled receptor widely expressed throughout the 
central nervous system (CNS). Disruption of 
dopamine signaling is implied in diseases including 
schizophrenia, Parkinson's and Huntington's disease 
(Oak et al., 2000). Recently Unland and colleagues 
identified DRD4 as a methylated candidate in 
pediatric CNS tumors, using a genome-wide 
methylation approach. Their analyses suggested 
DRD4 as a direct target of EZH2. In particular, they 
showed that depletion of EZH2 is sufficient to 
induce re-expression of DRD4, suggesting the role 
of EZH2 for DNA hypermethylation in the 
epigenetic inhibition of DRD4 (Unland et al., 
2014). 
Glioblastoma multiforme 
Note 
Overexpression of the EZH2 has been observed in 
different malignancies, including glioblastoma 
multiforme (GBM) (Venneti et al., 2013). Suvà and 
collaborators demonstrated that disruption of EZH2 
by DZNep, or its specific down-regulation by short 
hairpin RNA, strongly impairs GBM cancer stem 
cell self-renewal in vitro and tumor-initiating 
capacity in vivo. They also showed the direct 
transcriptional regulation of c-myc by EZH2, using 
genome-wide expression analysis of DZNep-treated 
GBM, suggesting its role as a valuable new 
therapeutic target for management of patients with 
GBM (Suvà et al., 2009). 
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